Parter Capital injects CHF 4.5m into Histide

The fresh capital has been earmarked for the expansion of Histide's intellectual property licensing pipeline and for the clinical development of the company's Recoding Therapeutics product, a therapy which controls a cell's biology. It will also be used to look into new diseases.

Parter Capital is a Swiss private equity firm focusing on research-based investments and spin-offs in the biotech and medtech segments.

Company
Founded in 2014, Schindellegi-based Histide has created a platform of microenvironments to control cells. The aim is to treat a variety of diseases through the regeneration of human body tissues. The cells come from different tissues and are at different stages of development.

People
Florian Kemmerich is CEO of Histide and life sciences partner at Parter Capital.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Early-stage
• Healthcare
• Switzerland
• Unq2015Jan